2022 American Society of Clinical Oncology (ASCO): Meeting highlights

被引:0
作者
Black, Peter C. [1 ]
Fallah-Rad, Nazanin [2 ]
Loblaw, Andrew [3 ]
Kassouf, Elie [4 ]
Keyes, Mira [5 ]
Basappa, Naveen S. [6 ]
Swaminath, Anand [7 ]
机构
[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Div Radiat Oncol, Toronto, ON, Canada
[4] Hop Cite Sante, Dept Oncol, Laval, PQ, Canada
[5] Univ British Columbia, Div Radiat Oncol, Vancouver, BC, Canada
[6] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2022年 / 16卷 / 09期
关键词
CHECKMATE; 274; SURVIVAL; TRIAL; CABAZITAXEL; SUNITINIB; THERAPY; PEMBRO; MCRPC; SCORE;
D O I
10.5489/cuaj.8097
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E499 / E504
页数:6
相关论文
共 37 条
[1]   Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A. [J].
Balar, Arjun Vasant ;
Kamat, Ashish M. ;
Kulkarni, Girish S. ;
Uchio, Edward M. ;
Boormans, Joost L. ;
Roumiguie, Mathieu ;
Krieger, Laurence Eliot Miles ;
Singer, Eric A. ;
Bajorin, Dean F. ;
Grivas, Petros ;
Seo, Ho Kyung ;
Nishiyama, Hiroyuki ;
Konety, Badrinath R. ;
Nam, Kijoeng ;
Zambon, Joao Paulo ;
Kapadia, Ekta ;
De Wit, Ronald .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[2]  
Beckermann K, 2022, J CLIN ONCOL, V40, P4599, DOI [10.1200/JCO.2022.40.16_, DOI 10.1200/JCO.2022.40.16]
[3]   Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial [J].
Birtle, Alison ;
Johnson, Mark ;
Chester, John ;
Jones, Robert ;
Dolling, David ;
Bryan, Richard T. ;
Harris, Christopher ;
Winterbottom, Andrew ;
Blacker, Anthony ;
Catto, James W. F. ;
Chakraborti, Prabir ;
Donovan, Jenny L. ;
Elliott, Paul Anthony ;
French, Ann ;
Jagdev, Satinder ;
Jenkins, Benjamin ;
Keeley, Francis Xavier, Jr. ;
Kockelbergh, Roger ;
Powles, Thomas ;
Wagstaff, John ;
Wilson, Caroline ;
Todd, Rachel ;
Lewis, Rebecca ;
Hall, Emma .
LANCET, 2020, 395 (10232) :1268-1277
[4]  
Cathomas R, 2022, J CLIN ONCOL, V40
[5]  
Chamie K, 2022, J CLIN ONCOL, V40
[6]  
Chanza NM, 2022, J CLIN ONCOL, V40
[7]  
Chmura SJ, 2022, J CLIN ONCOL, V40
[8]   A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm. [J].
Crabb, Simon J. ;
Hussain, Syed A. ;
Soulis, Eileen ;
Hinsley, Samantha ;
Dempsey, Laura ;
Trevethan, Avril ;
Song, Yee Pei ;
Barber, Jim ;
Frew, John A. ;
Gale, Joanna ;
Faust, Guy ;
Brock, Susannah Joy ;
McGovern, Ursula Brigid ;
Parikh, Omi ;
Enting, Deborah ;
Sundar, Santhanam ;
Ratnayake, Gihan ;
Lees, Kathryn ;
Powles, Thomas ;
Jones, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[9]  
Davis ID, 2022, J CLIN ONCOL, V40
[10]  
Dizman N, 2022, J CLIN ONCOL, V40